PharmaEssentia Updates Progress of Ropeginterferon Alfa-2b Clinical Program
WALTHAM, Mass., Dec. 5, 2018 /PRNewswire/ -- * 36 month analysis of ropeginterferon alfa-2b (Ropeg) phase III clinical data in Polycythemia Vera (PV) demonstrates superiority across three key aspects of disease control, including complete hematological response (CHR), disease burden, and molec...
AOP Orphan and PharmaEssentia Announce Pivotal Phase III Results for Ropeginterferon Alfa-2b in Polycythemia Vera at the American Society of Hematology (ASH) Annual Meeting 2016
VIENNA and TAIPEI, , Dec. 5, 2016 /PRNewswire/ -- * At 12 months of treatment ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) in Complete Hematologic Response (CHR) * PROUD-PV demonstrated a significantly better safety and tolerability profile of ropeginterferon alfa-2b ve...
PharmaEssentia Announces Phase III PROUD-PV Study Results to be Presented at ASH Annual Meeting Oral Presentation
TAIPEI, , Nov. 28, 2016 /PRNewswire/ -- PharmaEssentia Corporation
(Taipei Exchange:6446
